Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples